Study of Oncolytic Virus Treatment in Adults with Recurrent Glioblastoma Aged 18 to 70

What this Trial Is About

Researchers are evaluating the use of an oncolytic viral agent for treating recurrent glioblastoma, a type of brain cancer. This clinical trial aims to assess the safety, tolerability, and medical effects experienced by participants injected with the oncolytic virus. The study focuses on understanding the medical problems that may occur after administration of this investigational treatment. Participants will receive the oncolytic virus via intratumoral injection initially, followed by additional injections every 2 to 4 weeks, totaling 6 injections. During the study, physical examinations and various tests will be conducted every 2 to 4 weeks to monitor symptoms, blood test results, and imaging findings. The primary outcome measured is the maximum tolerated dose at 4 hours, 2 days, 7 days, and 14 days after administration. Throughout the trial, participants will undergo regular assessments including physical exams, hematological tests, and imaging scans to track their health and response to the treatment. Researchers will closely monitor safety and tolerability, recording symptoms and laboratory results. The total participation period includes the injection phase and follow-up assessments to evaluate treatment effects and side effects up to the study end date in 2026.

Clinical Study of Oncolytic Virus in Glioblastoma